Modernizing Mental Health Through Innovative Technology & Psychedelics

Mydecine Innovations Group Inc. (CNSX: MYCO) (OTCMKTS: MYCOF) (FSE:0NF) and its subsidiary MindLeap Health have built an advanced digital health platform that helps people connect with mental health specialists that can empower them to thrive and develop habits for a healthy mind.


An Advanced Digital Health Platform

MindLeap supports people looking to achieve personal transformations and overcome mental health challenges—it's the only platform the combines Telehealth and tracking.

Health & Recovery Coaching

Assist people in translating psychedelic experiences into positive changes that overcome addiction.

Track Your Mental Health

Track your mood, emotions, habits and progress towards improved well-being over time.

Investment Highlights

Massive Market Size

More than 300 million people suffer from depression worldwide, while the telemedicine market is estimated to be worth upwards of $30 billion—growing at a ~20% CAGR through 2025.

Near-term Launch

MindLeap's software platform was designed by leading psychologists and neuroscientists and is set to launch in the third quarter of 2020, providing a near-term catalyst for investors.

Mydecine Acquisition

Mydecine Innovations Group Inc. acquired 100% interest in MindLeap's Digital Telehealth Platform focused on the emerging psychedelics industry, to unlock synergies between the two companies.

Additional Mydecine Subsidiaries

NeuroPharm Inc.

NeuroPharm Inc. (NPI) is developing a unique and proprietary set of pharmaceutical and natural health products addressing mental wellness in vulnerable populations.

Mydecine Health Sciences

Mydecine Health Sciences (MHS) is a vertically integrated company developing novel fungtional© mushroom products and psychedelic medicines for healthy and vulnerable populations.


Download the Investor Presentation

Copyright © 2020. All rights reserved.